(Wynnewood, PA) – All eyes are on Philadelphia as it prepares to welcome the world’s foremost cancer researchers for the American Association of Cancer Research’s annual meeting, but, just west of city limits, Lankenau Institute for Medical Research (LIMR) is concluding a two-day conference on the rapidly expanding field of cancer immunochemotherapy.
LIMR, part of Main Line Health and located at Lankenau Medical Center, was selected as the host for the 4th International Conference on Immunochemotherapy, an event that welcomes cancer scientists and researchers from across the world. Guest speakers at this year’s conference included representatives from Dana Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, University of Paris Rene Descartes, and National Health Research Institute in Taiwan. LIMR President George Prendergast, PhD, says Lankenau was an ideal location for the annual meeting because of its early work in immunochemotherapy. More than a decade ago, LIMR researchers uncovered IDO1 inhibitors, drugs that disrupt the process by which tumors evade a patient’s immune system.
“Immunochemotherapy is a very exciting area of research, and one that we have been heavily involved in for more than a decade,” says Dr. Prendergast. “The future of cancer treatment will increasingly focus on how to harness a patient’s immune system to combat cancer.”
That future, says Prendergast, begins now. The first forays of the new immunochemotherapy regimens in clinical trials are currently being offered to cancer patients, and this week’s conference has highlighted exciting new areas of research.
“We’re learning and we’re building on each discovery. These conferences are crucial for collaboration and advancing the field of immunochemotherapy, and LIMR and Main Line Health are proud to have a continuing role in such an exciting field.”